2018
Vargová, Jana; Mikeš, Jaromír; Jendželovský, Rastislav; Mikešová, Lucia; Kuchárová, Barbora; Čulka, Ľubomír; Fedr, Radek; Remšík, Ján; Souček, Karel; Kozubík, Alois; Fedoročko, Peter
Hypericin affects cancer side populations via competitive inhibition of BCRP. Journal Article
In: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 99, pp. 511–522, 2018, ISSN: 1950-6007 0753-3322, (Place: France).
Abstract | Links | BibTeX | Tags: ABC transporters, Aldehyde Dehydrogenase/metabolism, Animals, Anthracenes, ATP Binding Cassette Transporter, Biomarkers, Cancer stem-like cells, Carcinogenesis/drug effects/metabolism/pathology, Cell Line, Cellular/drug effects/metabolism/pathology, Clone Cells, Drug resistance, Humans, Hypericin, Member 1/metabolism, Member 2/*metabolism, Mice, Neoplasm Proteins/*metabolism, Neoplasms/*metabolism/*pathology, Neoplastic Stem Cells/drug effects/metabolism/pathology, Perylene/*analogs & derivatives/pharmacology, Phenotype, SCID, Side population, Side-Population Cells/drug effects/*pathology, Spheroids, St. John’s wort, Subfamily B, Subfamily G, Substrate Specificity/drug effects, Survival Analysis, Tumor, Tumor/metabolism
@article{vargova_hypericin_2018,
title = {Hypericin affects cancer side populations via competitive inhibition of BCRP.},
author = {Jana Vargová and Jaromír Mikeš and Rastislav Jendželovský and Lucia Mikešová and Barbora Kuchárová and Ľubomír Čulka and Radek Fedr and Ján Remšík and Karel Souček and Alois Kozubík and Peter Fedoročko},
doi = {10.1016/j.biopha.2018.01.074},
issn = {1950-6007 0753-3322},
year = {2018},
date = {2018-03-01},
journal = {Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie},
volume = {99},
pages = {511–522},
abstract = {OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.},
note = {Place: France},
keywords = {ABC transporters, Aldehyde Dehydrogenase/metabolism, Animals, Anthracenes, ATP Binding Cassette Transporter, Biomarkers, Cancer stem-like cells, Carcinogenesis/drug effects/metabolism/pathology, Cell Line, Cellular/drug effects/metabolism/pathology, Clone Cells, Drug resistance, Humans, Hypericin, Member 1/metabolism, Member 2/*metabolism, Mice, Neoplasm Proteins/*metabolism, Neoplasms/*metabolism/*pathology, Neoplastic Stem Cells/drug effects/metabolism/pathology, Perylene/*analogs & derivatives/pharmacology, Phenotype, SCID, Side population, Side-Population Cells/drug effects/*pathology, Spheroids, St. John’s wort, Subfamily B, Subfamily G, Substrate Specificity/drug effects, Survival Analysis, Tumor, Tumor/metabolism},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.
2013
Fedr, Radek; Pernicová, Zuzana; Slabáková, Eva; Straková, Nicol; Bouchal, Jan; Grepl, Michal; Kozubík, Alois; Souček, Karel
Automatic cell cloning assay for determining the clonogenic capacity of cancer and cancer stem-like cells. Journal Article
In: Cytometry. Part A : the journal of the International Society for Analytical Cytology, vol. 83, no. 5, pp. 472–482, 2013, ISSN: 1552-4930 1552-4922, (Place: United States).
Abstract | Links | BibTeX | Tags: *Cell Proliferation, AC133 Antigen, Antigens, Biomarkers, CD/metabolism, Cell Adhesion Molecules/metabolism, Cell Line, Cell Survival, Colonic Neoplasms/metabolism/*pathology, Flow Cytometry/*methods, Glycoproteins/metabolism, Humans, Hyaluronan Receptors/metabolism, In Vitro Techniques, Integrin alpha6/metabolism, Male, Neoplasm/metabolism, Neoplastic Stem Cells/metabolism/*pathology, Peptides/metabolism, Prostatic Neoplasms/metabolism/*pathology, Tumor, Tumor Stem Cell Assay/*methods, Tumor/metabolism
@article{fedr_automatic_2013,
title = {Automatic cell cloning assay for determining the clonogenic capacity of cancer and cancer stem-like cells.},
author = {Radek Fedr and Zuzana Pernicová and Eva Slabáková and Nicol Straková and Jan Bouchal and Michal Grepl and Alois Kozubík and Karel Souček},
doi = {10.1002/cyto.a.22273},
issn = {1552-4930 1552-4922},
year = {2013},
date = {2013-05-01},
journal = {Cytometry. Part A : the journal of the International Society for Analytical Cytology},
volume = {83},
number = {5},
pages = {472–482},
abstract = {The clonogenic assay is a well-established in vitro method for testing the survival and proliferative capability of cells. It can be used to determine the cytotoxic effects of various treatments including chemotherapeutics and ionizing radiation. However, this approach can also characterize cells with different phenotypes and biological properties, such as stem cells or cancer stem cells. In this study, we implemented a faster and more precise method for assessing the cloning efficiency of cancer stem-like cells that were characterized and separated using a high-speed cell sorter. Cell plating onto a microplate using an automatic cell deposition unit was performed in a single-cell or dilution rank mode by the fluorescence-activated cell sorting method. We tested the new automatic cell-cloning assay (ACCA) on selected cancer cell lines and compared it with the manual approach. The obtained results were also compared with the results of the limiting dilution assay for different cell lines. We applied the ACCA to analyze the cloning capacity of different subpopulations of prostate and colon cancer cells based on the expression of the characteristic markers of stem (CD44 and CD133) and cancer stem cells (TROP-2, CD49f, and CD44). Our results revealed that the novel ACCA is a straightforward approach for determining the clonogenic capacity of cancer stem-like cells identified in both cell lines and patient samples.},
note = {Place: United States},
keywords = {*Cell Proliferation, AC133 Antigen, Antigens, Biomarkers, CD/metabolism, Cell Adhesion Molecules/metabolism, Cell Line, Cell Survival, Colonic Neoplasms/metabolism/*pathology, Flow Cytometry/*methods, Glycoproteins/metabolism, Humans, Hyaluronan Receptors/metabolism, In Vitro Techniques, Integrin alpha6/metabolism, Male, Neoplasm/metabolism, Neoplastic Stem Cells/metabolism/*pathology, Peptides/metabolism, Prostatic Neoplasms/metabolism/*pathology, Tumor, Tumor Stem Cell Assay/*methods, Tumor/metabolism},
pubstate = {published},
tppubtype = {article}
}
The clonogenic assay is a well-established in vitro method for testing the survival and proliferative capability of cells. It can be used to determine the cytotoxic effects of various treatments including chemotherapeutics and ionizing radiation. However, this approach can also characterize cells with different phenotypes and biological properties, such as stem cells or cancer stem cells. In this study, we implemented a faster and more precise method for assessing the cloning efficiency of cancer stem-like cells that were characterized and separated using a high-speed cell sorter. Cell plating onto a microplate using an automatic cell deposition unit was performed in a single-cell or dilution rank mode by the fluorescence-activated cell sorting method. We tested the new automatic cell-cloning assay (ACCA) on selected cancer cell lines and compared it with the manual approach. The obtained results were also compared with the results of the limiting dilution assay for different cell lines. We applied the ACCA to analyze the cloning capacity of different subpopulations of prostate and colon cancer cells based on the expression of the characteristic markers of stem (CD44 and CD133) and cancer stem cells (TROP-2, CD49f, and CD44). Our results revealed that the novel ACCA is a straightforward approach for determining the clonogenic capacity of cancer stem-like cells identified in both cell lines and patient samples.